Clinical trials
Enrolling by invitation Carcinoma, Non-Small-Cell Lung trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2011 | 1 |
| 2019 | 1 |
| 2021 | 3 |
| 2023 | 4 |
| 2024 | 9 |
| 2025 | 6 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Enrolling by invitation | 28 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Shanghai Chest Hospital | 2 |
| A2 Biotherapeutics Inc. | 1 |
| Avistone Biotechnology Co., Ltd. | 1 |
| Azienda Ospedaliero, Universitaria Pisana | 1 |
| Biogenea Pharmaceuticals Ltd. | 1 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| Chinese Academy of Medical Sciences | 1 |
| Fujian Cancer Hospital | 1 |
| Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental | 1 |
| Henan Cancer Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Carcinoma, Non-Small-Cell Lung | 28 |
| Lung Neoplasms | 5 |
| Colorectal Neoplasms | 3 |
| Breast Neoplasms | 2 |
| Esophageal Neoplasms | 2 |
| Melanoma | 2 |
| Mesothelioma | 2 |
| Neoplasm Metastasis | 2 |
| Neoplasms | 2 |
| Small Cell Lung Carcinoma | 2 |
Trials
Showing 51 to 28 of 28. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.